Patent US4737578A successfully refreshed from Google Patents.
US4737578A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human inhibin
Assignee: Salk Institute for Biological Studies
•
Filing: 1986-04-07
•
Granted: 1988-04-12
•
Expires: 2006-04-07
Abstract
Abstract Proteins with inhibin activity having a weight of about 32,000 daltons. The molecule is composed of two chains having molecular weights of about 18,000 and about 14,000 daltons, respectively, which are bound together by disulfide bonding. The 18K chain is obtained from the human inhibin gene and has the formula: H-Ser-Thr-Pro-Leu-Met-Ser-Trp-Pro-Trp-Ser-Pro-Ser-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Ala-His-Ala-Asn-Cys-His-Arg-Val-Ala-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Glu-Arg-Trp-Ile-Val-Tyr-Pro-Pro-Ser-Phe-R.sub.65 -Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-His-Ile-Pro-Pro-Asn-Leu-Ser-Leu-Pro-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Ala-Gln-Pro-Tyr-Ser-Leu-Leu-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Pro-Leu-His-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-P e-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH, wherein R 65 is Ile or Arg. The 18K chain is connected by disulfide bonding to the 14K chain.
Inventors
- 👤 Ronald M. Evans
- 👤 Michael G. Rosenfeld
- 👤 Gail Cerelli
- 👤 Kelly E. Mayo
- 👤 Joachim Spiess
- 👤 Jean E. F. Rivier
- 👤 Wylie W. Vale, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:36
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/26
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
48 words
A synthetic protein produced using recombinant DNA techniques or the like having two chains interconnected by disulfide bonding, said first chain having formula: H-Ser-Thr-Pro-Leu-Met-Ser-Trp-Pro-Trp-Ser-Pro-Ser-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Ala-His-Ala-Asn-Cys-His-Arg-Val-Ala-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Glu-Arg-Trp-Ile-Val-Tyr-Pro-Pro-Ser-Phe-R.sub.65 -Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-His-Ile-Pro-Pro-Asn-Leu-Ser-Leu-Pro-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Ala-Gln-Pro-Tyr-Ser-Leu-Leu-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Pro-Leu-His-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Ly -Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH, wherein R 65 is Ile or Arg, and said second chain having either the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val-Ile-A n-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH, or the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val-Val-A n-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH.
Claim 2
Dependent Claim
48 words
A synthetic protein produced using recombinant DNA techniques or the like having two chains interconnected by disulfide bonding, said first chain having formula: H-Ser-Thr-Pro-Leu-Met-Ser-Trp-Pro-Trp-Ser-Pro-Ser-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Ala-His-Ala-Asn-Cys-His-Arg-Val-Ala-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Glu-Arg-Trp-Ile-Val-Tyr-Pro-Pro-Ser-Phe-R.sub.65 -Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-His-Ile-Pro-Pro-Asn-Leu-Ser-Leu-Pro-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Ala-Gln-Pro-Tyr-Ser-Leu-Leu-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Pro-Leu-His-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Ly -Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH, wherein R 65 is Ile or Arg, and said second chain having either the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val-Ile-A n-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH, or the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val-Val-A n-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH.
Claim 3
Dependent Claim
12 words
A synthetic peptide according to claim 1 wherein R 65 is Ile.
Claim 4
Dependent Claim
12 words
A synthetic peptide according to claim 1 wherein R 65 is Arg.
Claim 5
Dependent Claim
29 words
A synthetic inhibin protein having the sequence: Ser-Thr-Pro-Leu-Met-Ser-Trp-Pro-Trp-Ser-Pro-Ser-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Ala-His-Ala-Asn-Cys-His-Arg-Val-Ala-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Glu-Arg-Trp-Ile-Val-Tyr-Pro-Pro-Ser-Phe-R 65 -Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-His-Ile-Pro-Pro-Asn-Leu-Ser-Leu-Pro-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Ala-Gln-Pro-Tyr-Ser-Leu-Leu-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Pro-Leu-His-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Ly -Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile or the sequence: Met-Val-Leu-His-Leu-Leu-Leu-Phe-Leu-Leu-Leu-Thr-Pro-Gln-Gly-Gly-His-Ser-Cys-Gln-Gly-Leu-Glu-Leu-Ala-Arg-Glu-Leu-Val-Leu-Ala-Lys-Val-Arg-Ala-Leu-Phe-Leu-Asp-Ala-Leu-Gly-Pro-Pro-Ala-Val-Thr-Arg-Glu-Gly-Gly-Asp-Pro-Gly-Val-Arg-Arg-Leu-Pro-Arg-Arg-His-Ala-Leu Gly-Gly-Phe-Thr-His-Arg-Gly-Ser-Glu-Pro-Glu-Glu-Glu-Glu-Asp-Val-Ser-Gln-Ala-Ile-Leu-Phe-Pro-Ala-Thr-Asp-Ala-Ser-Cys-Glu-Asp-Lys-Ser-Ala-Ala-Arg-Gly-Leu-Ala-Gln-Glu-Ala-Glu-Glu-Gly-Leu-Phe-Arg-Tyr-Met-Phe-Arg-Pro-Ser-Gln-His-Thr-Arg-Ser-Arg-Gln-Val-Thr-Ser Ala-Gln-Leu-Trp-Phe-His-Thr-Gly-Leu-Asp-Arg-Gln-Gly-Thr-Ala-Ala-Ser-Asn-Ser-Ser-Glu-Pro-Leu-Leu-Gly-Leu-Leu-Ala-Leu-Ser-Pro-Gly-Gly-Pro-Val-Ala-Val-Pro-Met-Ser-Leu-Gly-His-Ala-Pro-Pro-His-Trp-Ala-Val-Leu-His-Leu-Ala-Thr-Ser-Ala-Leu-Ser-Leu-Leu-Thr-His-Pro Val-Leu-Val-Leu-Leu-Leu-Arg-Cys-Pro-Leu-Cys-Thr-Cys-Ser-Ala-Arg-Pro-Glu-Ala-Thr-Pro-Phe-Leu-Val-Ala-His-Thr-Arg-Thr-Arg-Pro-Pro-Ser-Gly-Gly-Glu-Arg-Ala-Arg-Arg-Ser-Thr-Pro-Leu-Met-Ser-Trp-Pro-Trp-Ser-Pro-Ser-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro Ala-Ala-His-Ala-Asn-Cys-His-Arg-Val-Ala-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Glu-Arg-Trp-Ile-Val-Tyr-Pro-Pro-Ser-Phe-R 65 -Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-His-Ile-Pro-Pro-Asn-Leu-Ser-Leu-Pro-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Ala-Gln-Pro-Tyr-Ser-Leu-Leu-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Pro-Leu-His-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Ly -Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile, wherein R 65 is Ile or Arg.
Claim 6
Dependent Claim
29 words
A synthetic inhibin protein having the sequence: Ser-Thr-Pro-Leu-Met-Ser-Trp-Pro-Trp-Ser-Pro-Ser-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Ala-His-Ala-Asn-Cys-His-Arg-Val-Ala-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Glu-Arg-Trp-Ile-Val-Tyr-Pro-Pro-Ser-Phe-R 65 -Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-His-Ile-Pro-Pro-Asn-Leu-Ser-Leu-Pro-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Ala-Gln-Pro-Tyr-Ser-Leu-Leu-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Pro-Leu-His-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Ly -Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile or the sequence: Met-Val-Leu-His-Leu-Leu-Leu-Phe-Leu-Leu-Leu-Thr-Pro-Gln-Gly-Gly-His-Ser-Cys-Gln-Gly-Leu-Glu-Leu-Ala-Arg-Glu-Leu-Val-Leu-Ala-Lys-Val-Arg-Ala-Leu-Phe-Leu-Asp-Ala-Leu-Gly-Pro-Pro-Ala-Val-Thr-Arg-Glu-Gly-Gly-Asp-Pro-Gly-Val-Arg-Arg-Leu-Pro-Arg-Arg-His-Ala-Leu Gly-Gly-Phe-Thr-His-Arg-Gly-Ser-Glu-Pro-Glu-Glu-Glu-Glu-Asp-Val-Ser-Gln-Ala-Ile-Leu-Phe-Pro-Ala-Thr-Asp-Ala-Ser-Cys-Glu-Asp-Lys-Ser-Ala-Ala-Arg-Gly-Leu-Ala-Gln-Glu-Ala-Glu-Glu-Gly-Leu-Phe-Arg-Tyr-Met-Phe-Arg-Pro-Ser-Gln-His-Thr-Arg-Ser-Arg-Gln-Val-Thr-Ser Ala-Gln-Leu-Trp-Phe-His-Thr-Gly-Leu-Asp-Arg-Gln-Gly-Thr-Ala-Ala-Ser-Asn-Ser-Ser-Glu-Pro-Leu-Leu-Gly-Leu-Leu-Ala-Leu-Ser-Pro-Gly-Gly-Pro-Val-Ala-Val-Pro-Met-Ser-Leu-Gly-His-Ala-Pro-Pro-His-Trp-Ala-Val-Leu-His-Leu-Ala-Thr-Ser-Ala-Leu-Ser-Leu-Leu-Thr-His-Pro Val-Leu-Val-Leu-Leu-Leu-Arg-Cys-Pro-Leu-Cys-Thr-Cys-Ser-Ala-Arg-Pro-Glu-Ala-Thr-Pro-Phe-Leu-Val-Ala-His-Thr-Arg-Thr-Arg-Pro-Pro-Ser-Gly-Gly-Glu-Arg-Ala-Arg-Arg-Ser-Thr-Pro-Leu-Met-Ser-Trp-Pro-Trp-Ser-Pro-Ser-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro Ala-Ala-His-Ala-Asn-Cys-His-Arg-Val-Ala-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Glu-Arg-Trp-Ile-Val-Tyr-Pro-Pro-Ser-Phe-R 65 -Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-His-Ile-Pro-Pro-Asn-Leu-Ser-Leu-Pro-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Ala-Gln-Pro-Tyr-Ser-Leu-Leu-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Pro-Leu-His-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Ly -Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile, wherein R 65 is Ile or Arg.
Claim 7
Dependent Claim
11 words
A protein according to claim 4 wherein R 65 is Ile.
Claim 8
Dependent Claim
28 words
A synthetic inhibin protein segment of a protein in accordance with claim 4, which segment is effective to create antibodies which neutralize the FSH-release-inhibiting property of human inhibin.
Claim 9
Dependent Claim
29 words
A synthetic segment in accordance with claim 6 wherein said segment constitutes the N-terminal 6-residue sequence Ser-Thr-Pro-Leu-Met-Ser or the 25-residue sequence Ser-Thr-Pro-Leu-Met-Ser-Try-Pro-Trp-Ser-Pro-Ser-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala of the α-chain of of human inhibin.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-04-12 | 1991-10-12 | 1992-04-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-04-12 | 1995-10-12 | 1996-04-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-04-12 | 1999-10-12 | 2000-04-12 | $7700.00 | Window Closed / Lapsed |